Aro Biotherapeutics CEO Sue Dillon (L) and CSO Karyn O'Neil
Scoop: J&J-backed Aro Biotherapeutics eyes nine-figure raise with first trial on horizon
Aro Biotherapeutics is en route to the clinic, and a nine-figure capital infusion is in view.
The Philadelphia biotech is “in the process of raising …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
